Since its inception in 2015, ImCheck has raised approximately $85 million (Series A and B) from European and American equity investors to develop its unique immuno-oncology pipeline, further investigate the potential of its antibodies in autoimmune disease, and establish clinical operations and corporate development activities in the US.
The first clinical trial of its drug candidate ICT01 was initiated in 2020 in various cancer indications (blood and solid tumors). As a first-in-class, immune system-activating mAb, ImCheck is encouraged to see rapid and potent dose-dependent activity of ICT01 without any safety concerns in the patients treated to date (data presented at AACR Annual Meeting 2021).
Our investors
Hans Henrik CHRISTENSEN
Supportive EU and US Financial and Strategic Investors
The capital we have raised to date validates the unique potential of ImCheck’s leadership position in developing antibodies targeting butyrophilins, a superfamily of targets with tremendous potential in immuno-oncology as well as other immune system related indications.